Related Experiment Video
Updated: Apr 20, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach
Daniela Bertacchi1, Fabio Zucca2, Sergio Foresti3
1Università di Milano-Bicocca Dipartimento di Matematica e Applicazioni, Via Cozzi 53, 20125 Milano, Italy daniela.bertacchi@unimib.it.
Mathematical Medicine and Biology : a Journal of the IMA
|November 16, 2014
Summary
For chronic hepatitis B virus (HBV) infection, early combination therapy is superior to sequential monotherapy. Combination therapy delays drug resistance and increases the chances of viral eradication.
Area of Science:
- Virology
- Mathematical Biology
- Pharmacology
Background:
- Sequential monotherapy is standard for chronic hepatitis B virus (HBV) infection.
- Drug-resistant HBV variants can emerge during sequential therapy.
- The efficacy of combination therapy versus sequential therapy in preventing resistance is unclear.
Purpose of the Study:
- To compare the effectiveness of sequential monotherapy and combination therapy in managing chronic HBV infection.
- To model the emergence of drug-resistant HBV strains under different therapeutic strategies.
- To determine if combination therapy can delay or prevent the development of drug resistance.
Main Methods:
- Development of a stochastic mathematical model for HBV infection dynamics.
- Comparison of stochastic simulations with a deterministic approximation of the model.
- Simulation of HBV treatment using both sequential and contemporaneous (combination) drug administration.
- Analysis of the time to detectability of drug-resistant HBV strains.
Main Results:
- Stochastic simulations are more appropriate than deterministic models for studying mutation dynamics.
- Early combination therapy significantly delays the emergence of drug-resistant HBV strains.
- Combination therapy leads to longer periods of being drug resistance-free compared to sequential therapy.
- Viral eradication is more frequently achieved with combination therapy.
Conclusions:
- Combination therapy is a more effective strategy than sequential monotherapy for chronic HBV infection.
- Initiating combination therapy early is crucial for preventing drug resistance.
- Combination therapy offers a better prospect for achieving viral eradication in HBV patients.
Related Concept Videos
01:10Retrovirus Life Cycles
50.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.9K
01:25Hepatitis
66
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
66
01:27Combined Effects of Drugs: Synergism
8.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
8.0K
01:28Viral Hepatitis I: Introduction
15
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
15
01:28Pulmonary Tuberculosis V
947
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
947
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K